BB Good human data, but mixed outcomes or surrogate markers. How we grade →Secondary analysis of RCT · DPP/DPPOS, about 1,700 people with B12 samples
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
V Aroda, S Edelstein, R Goldberg, W Knowler, S Marcovina, T Orchard et al. The Journal of Clinical Endocrinology & Metabolism. 2016.
- In plain language
- Low vitamin B12 was more common on metformin at 5 years (4.3% vs 2.3%); long-term use was linked to B12 deficiency and anemia.
- Limits
- Not significant at 13 years for low B12 alone; open-label metformin after year 3.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Metformin as an aging drug: what the evidence shows, and why the TAME trial has not started
- Source
- doi.org/10.1210/jc.2015-3754 · PubMed 26900641 · Free full text
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.